Skip to main content
Company
Management Team
Board of Directors
Scientific Advisory Board
Partnerships
Contact Us
Pipeline
Indications
Science
Galinpepimut-S: WT1 Targeting Immunotherapeutic
SLS009: Highly Selective CDK9 Inhibitor
Publications
Clinical Trials
Ongoing
Completed
Investors
Overview
News
Events & Presentations
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
Investor Resources
Careers
WT1 Antigen ranked by National Cancer Institute as a top priority for immunotherapy
Learn More
Corporate Governance
Home
Overview
Company
About SELLAS
Management
Board of Directors
Scientific Advisory Board
Partnerships
Contact
Sellas Pipeline
Indications
Galinpepimut-S (GPS) Therapy
Our Therapy
Wt1 Cancer Immunotherapy
Wt1 Immunotherapy Development
News
Pipeline
NELIPEPIMUT-S (NPS) Clincal Trials
Anagrelide CR Clinical Trials
Events & Presentations
Publications
Galinpepimut-S (GPS)
Stock Information
Stock Quote
Stock Chart
Historical Stock Quote
Investment Calculator
Indications
Analyst Coverage
Financials
Investors
Media Coverage
SEC Filings
Corporate Governance
Management
Board of Directors
Governance Documents
Committee Composition
Board Diversity Matrix
Investor Resources
Contact IR
Investor FAQs
Whistleblower
Information Request
Email Alerts
Derivative Litigation
Careers
Shareholder Letter
Governance Documents
Download year list
Date
Download
Description
December 26, 2017
Audit Committee Charter
(opens in new window)
244 KB
December 23, 2017
Code of Business Conduct and Ethics
(opens in new window)
December 22, 2017
Compensation Committee Charter
(opens in new window)
105 KB
December 20, 2017
Corporate Governance Guidelines
(opens in new window)
137 KB
December 19, 2017
Nominating and Corporate Governance Committee Charter
(opens in new window)
83 KB
Committee Composition
Audit
Compensation
Nominating / Governance
Science
John Varian
Katherine Bach Kalin
David A. Scheinberg, M.D., Ph.D.
Angelos M. Stergiou, M.D., Sc.D. h.c.
Robert L. Van Nostrand
Jane Wasman
Chair of the Board
Member
Chair
Board Diversity Matrix
Total Number of Directors
6
Part I: Gender Identity
Female
Male
Non-Binary
Did Not Disclose Gender
Directors
2
4
0
0
Part II: Demographic Background
African American or Black
0
0
0
0
Alaskan Native or American Indian
0
0
0
0
Asian
0
0
0
0
Hispanic or Latinx
0
0
0
0
Native Hawaiian or Pacific Islander
0
0
0
0
White
2
4
0
0
Two or More Races or Ethnicities
0
0
0
0
LGBTQ+
0
Did Not Disclose Demographic Background
0
2023 Board Diversity Matrix
Total Number of Directors
6
Part I: Gender Identity
Female
Male
Non-Binary
Did Not Disclose Gender
Directors
2
4
0
0
Part II: Demographic Background
African American or Black
0
0
0
0
Alaskan Native or American Indian
0
0
0
0
Asian
0
0
0
0
Hispanic or Latinx
0
0
0
0
Native Hawaiian or Pacific Islander
0
0
0
0
White
2
4
0
0
Two or More Races or Ethnicities
0
0
0
0
LGBTQ+
0
Did Not Disclose Demographic Background
0
7 Times Square, Suite 2503
New York, NY 10036
646-200-5278
info@sellaslife.com
Company
About SELLAS
Management Team
Board of Directors
Scientific Advisory Board
Partnerships
Contact Us
Pipeline
Indications
Science
Galinpepimut-S: WT1 Targeting Immunotherapeutic
SLS009: Highly Selective CDK9 Inhibitor
Publications
Clinical Trials
Ongoing
Completed
Investors
Careers
Privacy Policy
Terms
Sitemap
©
SELLAS Life Sciences Group Inc. All Rights Reserved